Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of cangrelor versus usual care in percutaneous coronary intervention
2006-003935-56Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Aug 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cangrelor in coronary arteriosclerosis (2 arms), sponsored by The Medicines Company. Primary endpoint: Primary composite efficacy endpoint. Started Aug 2006; status: completed.
02
Drugs
cangrelor
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2006-003935-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003935-56.